Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Divi's Laboratories is a Hyderabad-based manufacturer of active pharmaceutical ingredients with two engines: large-scale generic APIs (where it is a global top-two producer in molecules like naproxen and dextromethorphan) and custom synthesis/CDMO work for global innovator pharma companies, including contrast-media intermediates and peptide building blocks (a beneficiary of GLP-1 supply chains). It also makes nutraceutical ingredients (carotenoids). Its moat is process chemistry excellence, massive manufacturing scale at two Vizag-area campuses and a clean regulatory track record.
It is among the world's largest API manufacturers and India's most valuable pure-play API/CDMO company.
Divi's Laboratories Ltd. is a constituent of NIFTY 100, NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY NEXT 50, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Divi's Laboratories Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 96.75 | 82.53 | 60.27 |
| Book value / share (₹) | 632.49 | 564.87 | 512.11 |
| Return on equity | 15.3% | 14.6% | 11.8% |
| Return on capital employed | 16.6% | 16.6% | 12.9% |
| Operating margin | 28.2% | 27.4% | 23.3% |
| Net margin | 24.3% | 23.4% | 20.4% |
| EBITDA | ₹3,441 Cr | ₹2,968 Cr | ₹2,205 Cr |
| Free cash flow | ₹218 Cr | ₹215 Cr | ₹258 Cr |
| Total debt | ₹0 Cr | ₹2 Cr | ₹0 Cr |
| Debt to equity | 0.00 | 0.00 | 0.00 |
| Interest coverage | 129.5 | 1283.0 | 609.0 |
| Current ratio | 5.43 | 6.94 | 7.57 |
| Shares outstanding | 26,50,00,000 | 26,50,00,000 | 26,50,00,000 |
Open the full income statement, balance sheet and cash flow for DIVISLAB →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.